Get the Stockscreener App
8.5416
0.21%
-0.0184
Passage Bio Inc stock is traded at $8.5416, with a volume of 23,521.
It is down -0.21% in the last 24 hours and up +19.58% over the past month.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
See More
Previous Close:
$8.56
Open:
$8.52
24h Volume:
23,521
Relative Volume:
0.66
Market Cap:
$27.15M
Revenue:
-
Net Income/Loss:
$-68.80M
P/E Ratio:
-7.3005
EPS:
-1.17
Net Cash Flow:
$-59.06M
1W Performance:
+0.25%
1M Performance:
+19.58%
6M Performance:
+2,209%
1Y Performance:
+1,275%
1-Day Range:
$8.125
$9.00
1-Week Range:
$7.13
$9.00
52-Week Range:
$0.257
$9.90
Passage Bio Inc Stock (PASG) Company Profile
Name
Passage Bio Inc
Sector
Industry
Phone
(267) 866-0312
Address
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
8.5416 | 27.21M | 0 | -68.80M | -59.06M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.21 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.27 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.32 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.99 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.65 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Sep-03-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-08-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-19-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-01-21 | Initiated | Raymond James | Outperform |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Mar-04-21 | Upgrade | Goldman | Neutral → Buy |
| Feb-04-21 | Initiated | Guggenheim | Buy |
| Jan-25-21 | Initiated | Wedbush | Outperform |
| Jan-04-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Aug-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-25-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-25-20 | Initiated | Chardan Capital Markets | Buy |
| Mar-24-20 | Initiated | Cowen | Outperform |
| Mar-24-20 | Initiated | Goldman | Buy |
| Mar-24-20 | Initiated | JP Morgan | Overweight |
View All
Passage Bio Inc Stock (PASG) Latest News
Lucid Capital Markets initiates Passage Bio stock with Buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Passage Bio stock with Buy rating - Investing.com India
Will Salona Cotspin Limited Benefit From Broader Market BounceLow Risk Investment Ideas & Maximize Gains Professionally - earlytimes.in
Passage Bio (PASG) Price Target Decreased by 45.15% to 33.15 - MSN
How Passage Bio Inc. stock compares to market leadersInsider Selling & AI Powered Market Trend Analysis - newser.com
Is Passage Bio Inc. stock bottoming out2025 Volatility Report & Proven Capital Preservation Tips - newser.com
Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates - MSN
How Passage Bio Inc. stock reacts to Fed rate cuts2025 Momentum Check & Low Risk High Win Rate Picks - newser.com
Applying chart zones and confluence areas to Passage Bio Inc.2025 Bull vs Bear & Safe Swing Trade Setups - newser.com
What momentum shifts mean for Passage Bio Inc.July 2025 Technicals & Safe Entry Trade Reports - newser.com
Chardan Capital Expects Reduced Earnings for Passage Bio - Defense World
Passage Bio Inc. stock trendline breakdownWeekly Trade Recap & Weekly Return Optimization Alerts - newser.com
Ranking Passage Bio Inc. among high performing stocks via toolsQuarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Passage Bio, Inc.Common Stock (NQ: PASG - FinancialContent
Using economic indicators to assess Passage Bio Inc. potentialQuarterly Earnings Report & Technical Confirmation Trade Alerts - newser.com
How Passage Bio Inc. stock reacts to global recession fearsEarnings Miss & Real-Time Volume Triggers - newser.com
Passage Bio Inc Stock Analysis and ForecastREITs Market Trends & Low Cost Wealth Plans - earlytimes.in
Chardan Capital Raises Passage Bio (NASDAQ:PASG) Price Target to $21.00 - Defense World
Passage Bio (NASDAQ:PASG) Price Target Raised to $21.00 - Defense World
Is Passage Bio Inc. stock a contrarian buyJuly 2025 Final Week & Weekly Stock Breakout Alerts - Fundação Cultural do Pará
What is Wedbush’s Forecast for Passage Bio FY2025 Earnings? - Defense World
Will Passage Bio Inc. price bounce be sustainableJuly 2025 Summary & Low Risk High Reward Ideas - newser.com
Why Passage Bio Inc. stock could rally in 2025Weekly Trend Recap & Stock Portfolio Risk Control - newser.com
Why Passage Bio Inc. stock remains a top recommendationEarnings Growth Report & Low Drawdown Investment Ideas - newser.com
Chardan Capital Raises Price Target on Passage Bio (PASG) to $21 - GuruFocus
Chardan Raises Price Target on Passage Bio to $21 From $6, Keeps Buy Rating - MarketScreener
3 Best Biotech Stocks to Buy Now, 11/12/2025, According to Top Analysts - TipRanks
Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN
Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF) and Passage Bio (PASG) - The Globe and Mail
Passage Bio Cuts Losses And Gains Analysts’ Confidence - Finimize
PASSAGE BIO, INC. Q3 Loss Decreases, Beats Estimates - Nasdaq
Passage Bio (PASG) Advances PBFT02 Clinical Trials and FDA Discu - GuruFocus
[10-Q] Passage BIO, Inc. Quarterly Earnings Report | PASG SEC FilingForm 10-Q - Stock Titan
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Passage Bio Q3 net loss narrows to $7.7 mln - MarketScreener
Passage Bio, Inc. Announces Active Enrollment in upliFT-D Study and Regulatory Alignment with FDA - Quiver Quantitative
PASG: Clinical trial progress, reduced net loss, and strong cash position support future milestones - TradingView
[8-K] Passage BIO, Inc. Reports Material Event | PASG SEC FilingForm 8-K - Stock Titan
Passage Bio (NASDAQ: PASG) narrows net loss to $7.7M, y/y from $19.3M as costs decline - Stock Titan
Passage Bio Inc Stock (PASG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Passage Bio Inc Stock (PASG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% Owner |
Sep 15 '25 |
Buy |
6.99 |
11,900 |
83,175 |
623,704 |
| Lynx1 Capital Management LP | 10% Owner |
Sep 11 '25 |
Buy |
6.96 |
325 |
2,261 |
592,021 |
| Lynx1 Capital Management LP | 10% Owner |
Jul 24 '25 |
Buy |
5.71 |
66,423 |
379,455 |
591,696 |
| Lynx1 Capital Management LP | 10% Owner |
Jul 23 '25 |
Buy |
5.74 |
49,302 |
283,033 |
525,273 |
| Lynx1 Capital Management LP | 10% Owner |
Jul 22 '25 |
Buy |
5.44 |
13,123 |
71,338 |
475,971 |
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):